Knight Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KHTRF research report →
Companywww.gud-knight.com
Knight Therapeutics Inc. , a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma.
- CEO
- Samira Sakhia
- IPO
- 2014
- Employees
- 745
- HQ
- Montreal, QC, CA
Price Chart
Valuation
- Market Cap
- $598.01M
- P/E
- 143.56
- P/S
- 1.57
- P/B
- 1.02
- EV/EBITDA
- 11.72
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 37.32%
- Op Margin
- 2.70%
- Net Margin
- 1.10%
- ROE
- 0.73%
- ROIC
- 1.07%
Growth & Income
- Revenue
- $449.72M · 21.12%
- Net Income
- $-5,369,619 · -223.95%
- EPS
- $-0.05 · -220.85%
- Op Income
- $-2,199,206
- FCF YoY
- 1321.39%
Performance & Tape
- 52W High
- $6.39
- 52W Low
- $4.07
- 50D MA
- $5.38
- 200D MA
- $4.65
- Beta
- 0.21
- Avg Volume
- 3.84K
Get TickerSpark's AI analysis on KHTRF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our KHTRF Coverage
We haven't published any research on KHTRF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KHTRF Report →